Both in Biotechnology
Champions Oncology vs Kalaris Therapeutics
Over the past year CSBR returned −24.9% and KLRS returned −54.3%; their daily moves had a correlation of 0.10.
CSBR −24.9% KLRS −54.3%Growth of $1, one year, split-adjusted
| Metric | CSBR | KLRS |
|---|---|---|
| Price | $4.79 | $2.90 |
| Market cap | $66.7M | $69.0M |
| Today | −2.84% | +1.93% |
| 1 month | −2.8% | −28.0% |
| 6 months | −18.0% | −45.3% |
| Year to date | −30.7% | −65.6% |
| 1 year | — | −48.3% |
| Revenue growth (YoY) | +8.8% | — |
| Gross margin | 50.5% | — |
| Net margin | −2.8% | — |
| P/E (TTM) | — | — |
| Price / sales | 1.1× | — |
| Net cash | $4.4M | $93.5M |
| Dividend yield | — | — |
| Volatility (60d) | 44.8% | 58.9% |
| Short % of float | 1.4% | 5.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).